Azurity Archives
News and events as they happenAzurity Pharmaceuticals Announces the Availability of JAVADIN™ (clonidine hydrochloride) Oral Solution
Woburn, MA—December 18, 2025—Azurity Pharmaceuticals, Inc. announced today the availability of JavadinTM (clonidine hydrochloride) oral solution, the only FDA-approved, immediate-release, ready-to-use oral liquid clonidine formulation for the treatment of hypertension in adult patients to lower blood pressure. Lowering blood pressure has been shown to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
Azurity Pharmaceuticals and Sebela Pharmaceuticals Announce the Sale of Sebela’s Bowel Prep Franchise to Azurity
Woburn, MA – November 17, 2025 – Azurity Pharmaceuticals and Sebela Pharmaceuticals announced today Azurity’s successful acquisition of Sebela’s Bowel Prep Franchise, including two leading bowel preparation therapies for colonoscopies.
Azurity Pharmaceuticals Announces FDA Approval of JAVADINTM (clonidine hydrochloride) Oral Solution
Woburn, MA—October 24, 2025—Azurity Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved JavadinTM (clonidine hydrochloride) oral solution, the only FDA-approved, immediate-release, ready-to-use oral liquid clonidine formulation for the treatment of hypertension in adult patients to lower blood pressure. Lowering blood pressure has been shown to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
ACA Pharma Named Exclusive Distributor for Feraheme® in Hong Kong, Macau, Greater Bay Area, Mainland China, and Singapore
New York, NY — October 23, 2025— ACA Pharma and Azurity Pharmaceuticals are pleased to announce that they have signed an exclusive distribution partnership agreement for ACA Pharma to commercialize Feraheme® (ferumoxytol injection) across Hong Kong, Macau, the Greater Bay Area (GBA), Mainland China, and Singapore.
